Filing Flows › Indivior Pharmaceuticals (INDV) › Q1 2026
Indivior Pharmaceuticals (INDV) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Indivior Pharmaceuticals (INDV) reported revenue of $317M for the first quarter 2026 (Q1 2026), +19% from a year earlier and -11% from the quarter before. Operating margin was 43.2%, net earnings $89.0M (28.1% of revenue).
Indivior Pharmaceuticals, Q1 2026: revenue $317M (+19% year over year), operating margin 43.2%, net earnings $89.0M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $317M | -11% | +19% |
| Gross profit | $277M | -5% | +25% |
| Operating profit | $137M | +69% | +108% |
| Net earnings | $89.0M | -13% | +89% |
| Operating cash flow | −$9.0M | — | -112% |
What changed
Revenue was $317.0M in Q1 2026, up 19% year over year and down 11% from the previous quarter.
Gross margin was 87.4%, up 4.3 points from Q1 2025. Operating profit was $137.0M, a 43.2% margin (up 18.4 points year over year). Of the extra revenue versus Q1 2025, 139% reached operating profit, above the 25% margin then. Operating expenses fell 10% while revenue rose 19%. Net earnings were $89.0M, up 89% year over year. The effective tax rate was 22.6%.
Operating cash flow was −$9.0M. Non-cash charges added back $2.0M of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items used $109.0M. Capital expenditures of $20.0M exceeded it, leaving free cash flow of −$29.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the first quarter 2026?
Indivior Pharmaceuticals (INDV) reported revenue of $317M for the first quarter 2026 (Q1 2026), +19% from a year earlier and -11% from the quarter before.
Was Indivior Pharmaceuticals profitable in the first quarter 2026?
Operating profit was $137M (43.2% of revenue) and net earnings $89.0M.